Skip to main content

Levels and avidity of antibodies to tetanus toxoid in children aged 1–15 years in Dar es Salaam and Bagamoyo, Tanzania

Buy Article:

$63.00 + tax (Refund Policy)

A study was undertaken to determine the serological response in children (aged 1-15 years) immunized with diphtheria-pertussis-tetanus vaccine (DPT) alone or with a tetanus toxoid (TT) booster dose under the Expanded Programme on Immunization in Dar es Salaam and Bagamoyo, Tanzania. Using an ELISA technique, serum levels of anti-TT antibody, antibody avidity and anti-TT IgG subclasses were determined in 138 apparently healthy children. Our findings revealed that 94.7% and 98% of children aged 1-5 years in Dar es Salaam and Bagamoyo, respectively, had anti-TT antibody levels above that considered protective (≥ 0.1 IU/ml). Among 6-15-year-old children, 53.3% in Dar es Salaam and 55% in Bagamoyo had anti-TT antibody levels ≥ 0.1 IU/ml. The avidity index of anti-TT antibodies was high in most of the younger children, 84.2% in Dar es Salaam and 92% in Bagamoyo. Significantly fewer older children in Dar es Salaam and Bagamoyo (53.3% and 50%, respectively) had high avidity index antibodies. The predominant anti-TT IgG subclasses were IgG1 and IgG3. It is concluded that the current DPT immunization schedule provides adequate tetanus immunity for children under 5. However, about half of the older children had no protection against tetanus.

Document Type: Research Article

Affiliations: 1: Department of Microbiology and Immunology, Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania 2: Department of Microbiology and Immunology, The Gade Institute, University of Bergen, Norway 3: Department of Microbiology and Immunology, The Gade Institute, University of Bergen and Blood Bank, Haukeland University Hospital, Bergen, Norway

Publication date: 01 December 2000

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content